Browse every story filed under this topic, curated from trusted publishers around the world.
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
Read full story →
STAT+: Eli Lilly enlists AI startup for next-generation gene editors
Eli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could …
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I …
STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedema
STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for …
Millie David to make Red Roses debut against Wales as England’s lock crisis deepens
Young Bristol wing David is primed for her first cap, but second row Lilli Ives Campion has joined a long …
Amazon Just Put the Biggest Trade of the Decade on the Wrong Side—and Big Pharma Is Paying for It
Amazon’s new GLP-1 pricing is dragging Novo Nordisk and Eli Lilly stocks lower.
Motorola Edge 70 Pro Launched in India With 6,500mAh Battery, 50-Megapixel Sony LYT-710 Camera: Price, Features
Motorola Edge 70 Pro has been launched in India, the tech firm announced on Wednesday. The handset is set to …
The Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pill
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and …
Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's …
Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition
Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal …
STAT+: Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride
Kelonia Therapeutics, a small biotech company, long struggled to stay afloat. Now it's been acquired by Eli Lilly for $3.25 …
You've seen all articles for #lilly.
Check back
soon
for new stories.